B. Sangro

机构：Centro de Investigación Biomédica en Red, Clinica Universidad de Navarra

发表论文 12 篇 · 总被引 372 次 · h-index 4

代表论文

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 343)
• 83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (2022 · Annals of Oncology · 被引 8)
• 206TiP SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma (2023 · Annals of Oncology · 被引 7)
• 148O Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): Results from CheckMate 9DW (2025 · Annals of Oncology · 被引 5)
• 150MO Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis (2025 · Annals of Oncology · 被引 3)
• 167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (2024 · Annals of Oncology · 被引 2)